Pfizer Inc
Change company Symbol lookup
Select an option...
PFE Pfizer Inc
GSBD Goldman Sachs BDC Inc
LTRN Lantern Pharma Inc
JGGC Jaguar Global Growth Corporation I
WHG Westwood Holdings Group Inc
BNOX Bionomics Ltd
PSO Pearson PLC
ERNA Eterna Therapeutics Inc
INDP Indaptus Therapeutics Inc
TSLX Sixth Street Specialty Lending Inc
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Closing Price
$32.09
Day's Change
-0.01 (-0.03%)
Bid
--
Ask
--
B/A Size
--
Day's High
32.32
Day's Low
31.77
Volume
(Average)
Volume:
28,197,588

10-day average volume:
29,410,702
28,197,588

Company Profile

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Valuation Ratios

Price/Earnings (TTM)
8.55x
Price/Sales (TTM)
2.33x
Price/Book (MRQ)
1.83x
Price/Cash Flow (TTM)
6.64x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend

Short Interest

September 2023
Current Month
49.9M
Previous Month
50.5M
Percent of Float
0.89%
Days to Cover
1.8080 Days

Share Information

PFE is in a share class of common stock
Float
5.6B
Shares Outstanding
5.6B
Institutions Holding Shares
3,829
68.35%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Albert BourlaChmn.
  • David M. DentonCFO
  • Angela HwangCorp.Exec.
  • Payal Sahni
  • Lidia L. FonsecaExec.VP

Address

Insider Trading

During the most recent quarter, 2K shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.